AUPH
Aurinia Pharmaceuticals Inc. [AUPH] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AUPH Stock Summary
Top 10 Correlated ETFs
AUPH
Top 10 Correlated Stocks
AUPH
In the News
AUPH Financial details
Company Rating
-
Market Cap
737.55M
Income
-78.02M
Revenue
175.51M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
300
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-16.64
Forward P/E
-
PEG
5.87
P/S
8.13
P/B
3.28
P/C
-
P/FCF
-34.09
Quick Ratio
5.09
Current Ratio
5.77
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.54
EPS next Y
-
EPS next Q
-
EPS this Y
-28.95%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-16.5%
Revenue last 5Y
253.49%
Revenue Q/Q
-17.28%
EPS Q/Q
101.91%
-
-
-
-
SMA20
15.16%
SMA50
13.6%
SMA100
13.32%
Inst Own
-
Inst Trans
-
ROA
-14%
ROE
-20%
ROC
-0.19%
Gross Margin
94%
Oper. Margin
-57%
Profit Margin
-49%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.85-12.43
52W High
-12.58%
52W Low
+162.25%
RSI
75.29
Rel Volume
3.63
Avg Volume
2.18M
Volume
7.93M
Perf Week
14.15%
Perf Month
32.45%
Perf Quarter
30.96%
Perf Half Y
31.95%
-
-
-
-
Beta
1.379
-
-
Volatility
0.53%, 0.68%
Prev Close
13.53%
Price
10.49
Change
15.27%
Company Profile
- Volume Average 2.18M
- Market Capitalization 737.55M
- Employee 300
- CEO Mr. Peter S. Greenleaf M.B.A.
- Headquarters Victoria,BC,CA
- IPO Date 2014-09-03
-
Website
https://www.auriniapharma.com 
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
